S&P 500   3,952.47 (+0.47%)
DOW   33,663.08 (+0.19%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,952.47 (+0.47%)
DOW   33,663.08 (+0.19%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,952.47 (+0.47%)
DOW   33,663.08 (+0.19%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
S&P 500   3,952.47 (+0.47%)
DOW   33,663.08 (+0.19%)
QQQ   283.40 (+1.02%)
AAPL   142.37 (+1.01%)
MSFT   246.96 (+1.06%)
META   115.70 (+1.55%)
GOOGL   94.18 (-0.80%)
AMZN   90.17 (+1.93%)
TSLA   173.31 (-0.42%)
NVDA   170.08 (+5.51%)
NIO   13.35 (+6.12%)
BABA   94.02 (+6.44%)
AMD   69.92 (-0.31%)
T   19.14 (-0.83%)
MU   55.15 (+2.47%)
CGC   3.01 (-7.10%)
F   13.12 (+0.15%)
GE   83.43 (-1.85%)
DIS   92.48 (+0.36%)
AMC   6.18 (+2.15%)
PYPL   74.50 (+0.11%)
PFE   51.52 (+2.55%)
NFLX   309.17 (+0.24%)
NASDAQ:CDMO

Avid Bioservices - CDMO Stock Forecast, Price & News

$12.63
-0.41 (-3.14%)
(As of 12/8/2022 02:49 PM ET)
Add
Compare
Today's Range
$12.61
$14.41
50-Day Range
$13.04
$19.12
52-Week Range
$11.30
$31.01
Volume
27,141 shs
Average Volume
483,431 shs
Market Capitalization
$785.21 million
P/E Ratio
7.47
Dividend Yield
N/A
Price Target
$26.67

Avid Bioservices MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.5% Upside
$24.33 Price Target
Short Interest
Bearish
8.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.25mentions of Avid Bioservices in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$409,964 Sold Last Quarter
Proj. Earnings Growth
275.00%
From $0.08 to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

70th out of 1,027 stocks

Pharmaceutical Preparations Industry

28th out of 503 stocks

CDMO stock logo

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Stock News Headlines

Avid Bioservices (NASDAQ:CDMO) Shares Down 3.2%
Avid Bioservices (NASDAQ:CDMO) Trading 4.2% Higher
Avid Bioservices, Inc. (NASDAQ: CDMO)
RBC Capital Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Is Avid Bioservices (CDMO) a Great Buy?
Read How Avid Bioservices Fared In Q4
Avid Bioservices's Earnings Outlook
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings
12/07/2021
Today
12/08/2022
Next Earnings (Estimated)
3/06/2023
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+111.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$127.67 million
Pretax Margin
6.87%

Debt

Sales & Book Value

Annual Sales
$119.60 million
Cash Flow
$0.31 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
61,011,000
Market Cap
$785.21 million
Optionable
Optionable
Beta
1.76

Key Executives

  • Mr. Nicholas Stewart Green B.Sc.Mr. Nicholas Stewart Green B.Sc. (Age 57)
    MBA, Pres, CEO & Director
    Comp: $1.54M
  • Mr. Daniel R. HartMr. Daniel R. Hart (Age 49)
    Chief Financial Officer
    Comp: $801.11k
  • Mr. Mark R. Ziebell J.D.Mr. Mark R. Ziebell J.D. (Age 58)
    VP, Gen. Counsel & Corp. Sec.
    Comp: $711.45k
  • Mr. Richard Richieri (Age 57)
    Chief Operations Officer
  • Mr. Matthew Kwietniak
    Chief Commercial Officer
  • Dr. Shelley P. M. Fussey (Age 56)
    VP of Intellectual Property
  • Ms. Tracy L. Kinjerski
    VP of Bus. Operations
  • Dr. Harold F. Dvorak M.D.
    Medical & Scientific Advisor
  • Prof. Alan J. Schroit
    Medical & Scientific Advisor
  • Prof. Rolf A. Brekken Ph.D.
    Medical & Scientific Advisor













CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price objectives for Avid Bioservices' stock. Their CDMO share price forecasts range from $20.00 to $28.00. On average, they predict the company's share price to reach $24.33 in the next twelve months. This suggests a possible upside of 86.6% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2022?

Avid Bioservices' stock was trading at $29.18 at the beginning of 2022. Since then, CDMO stock has decreased by 55.3% and is now trading at $13.04.
View the best growth stocks for 2022 here
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 3.56% and a net margin of 88.13%. During the same quarter in the prior year, the firm earned $0.01 EPS.

When did Avid Bioservices' stock split?

Avid Bioservices shares reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2023 earnings guidance on Tuesday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $145.00 million-$150.00 million, compared to the consensus revenue estimate of $143.81 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.53%), Vanguard Group Inc. (6.79%), State Street Corp (6.24%), Jennison Associates LLC (4.63%), Geneva Capital Management LLC (2.32%) and Artisan Partners Limited Partnership (1.84%). Insiders that own company stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends
.

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $13.04.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $810.70 million and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.69 on an earnings per share basis.

How many employees does Avid Bioservices have?

The company employs 252 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 12/8/2022 by MarketBeat.com Staff